| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
19,863 |
17,816 |
$2.09M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
8,797 |
7,682 |
$1.26M |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,523 |
1,258 |
$636K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,636 |
2,219 |
$611K |
| 71046 |
Radiologic examination, chest; 2 views |
9,026 |
6,994 |
$595K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
9,301 |
7,646 |
$509K |
| 80053 |
Comprehensive metabolic panel |
12,182 |
10,461 |
$490K |
| 71045 |
Radiologic examination, chest; single view |
9,106 |
5,423 |
$334K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,389 |
1,164 |
$315K |
| 36415 |
Collection of venous blood by venipuncture |
36,590 |
17,640 |
$291K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,730 |
3,030 |
$285K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
11,444 |
9,766 |
$263K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,335 |
2,015 |
$181K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,498 |
3,083 |
$173K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,643 |
1,328 |
$170K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
8,105 |
6,260 |
$158K |
| 80306 |
|
4,710 |
3,346 |
$148K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
860 |
768 |
$142K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,142 |
3,005 |
$133K |
| 80061 |
Lipid panel |
2,529 |
2,376 |
$130K |
| 87276 |
|
5,423 |
4,996 |
$119K |
| 87275 |
|
5,446 |
5,002 |
$115K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,827 |
1,494 |
$100K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
747 |
703 |
$98K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,327 |
1,184 |
$97K |
| 72100 |
|
1,084 |
903 |
$94K |
| 84484 |
|
2,607 |
1,941 |
$92K |
| 73562 |
|
826 |
721 |
$90K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
690 |
621 |
$74K |
| 73630 |
|
902 |
788 |
$72K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
303 |
256 |
$67K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,701 |
3,482 |
$63K |
| 71250 |
|
128 |
95 |
$62K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
733 |
665 |
$56K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
813 |
771 |
$52K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,895 |
1,808 |
$49K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
614 |
569 |
$49K |
| 83690 |
|
1,947 |
1,776 |
$48K |
| 81001 |
|
3,714 |
3,247 |
$48K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,384 |
1,133 |
$45K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
448 |
376 |
$43K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
464 |
405 |
$42K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
499 |
409 |
$40K |
| 82607 |
|
570 |
535 |
$39K |
| 74018 |
|
644 |
580 |
$38K |
| 82150 |
|
1,842 |
1,679 |
$36K |
| 83735 |
|
1,400 |
1,113 |
$33K |
| 87081 |
|
3,577 |
3,303 |
$33K |
| 73610 |
|
391 |
331 |
$31K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
3,069 |
2,780 |
$29K |
| 85027 |
|
1,633 |
1,502 |
$29K |
| 73030 |
|
298 |
239 |
$27K |
| 84439 |
|
1,080 |
1,038 |
$25K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
529 |
355 |
$24K |
| 82550 |
|
712 |
609 |
$23K |
| 73130 |
|
196 |
169 |
$19K |
| 81025 |
|
634 |
596 |
$18K |
| 87186 |
|
347 |
311 |
$16K |
| 87807 |
|
475 |
443 |
$13K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
31 |
27 |
$13K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
204 |
163 |
$12K |
| 83880 |
|
290 |
180 |
$11K |
| 82553 |
|
342 |
291 |
$11K |
| 94664 |
|
362 |
296 |
$10K |
| 84703 |
|
269 |
239 |
$9K |
| 82652 |
|
58 |
54 |
$8K |
| 85610 |
|
441 |
335 |
$8K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
244 |
185 |
$7K |
| 93971 |
|
47 |
36 |
$7K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
91 |
84 |
$6K |
| 81002 |
|
707 |
642 |
$5K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
79 |
55 |
$5K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
654 |
564 |
$5K |
| 87040 |
|
96 |
85 |
$4K |
| 72040 |
|
31 |
25 |
$4K |
| 80349 |
|
330 |
269 |
$4K |
| 96367 |
|
38 |
29 |
$3K |
| 83605 |
|
54 |
50 |
$3K |
| 87280 |
|
127 |
108 |
$2K |
| 94760 |
|
109 |
79 |
$2K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
2,176 |
1,531 |
$2K |
| 82803 |
|
21 |
16 |
$2K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
40 |
38 |
$2K |
| 85379 |
|
113 |
102 |
$2K |
| 85652 |
|
192 |
178 |
$2K |
| 85730 |
|
72 |
71 |
$2K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
393 |
363 |
$2K |
| 81003 |
|
235 |
210 |
$2K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
76 |
67 |
$1K |
| 0011A |
|
49 |
44 |
$1K |
| 96368 |
|
27 |
27 |
$1K |
| 0012A |
|
42 |
40 |
$1K |
| 80324 |
|
128 |
108 |
$821.35 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
131 |
124 |
$740.54 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
46 |
40 |
$696.90 |
| 80348 |
|
37 |
30 |
$498.88 |
| 36600 |
|
20 |
15 |
$482.29 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
14 |
14 |
$339.30 |
| 80346 |
|
13 |
12 |
$291.00 |
| 86308 |
|
24 |
13 |
$232.20 |
| 80361 |
|
31 |
27 |
$200.09 |
| 85651 |
|
19 |
13 |
$171.74 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19 |
13 |
$170.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
14 |
13 |
$155.40 |
| 80305 |
|
45 |
43 |
$13.78 |